213 related articles for article (PubMed ID: 37102326)
1. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
3. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.
Gentile I; Foggia M; Silvitelli M; Sardanelli A; Cattaneo L; Viceconte G
Virol J; 2023 Dec; 20(1):301. PubMed ID: 38102675
[TBL] [Abstract][Full Text] [Related]
4. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
5. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
[TBL] [Abstract][Full Text] [Related]
6. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
7. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
8. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
[TBL] [Abstract][Full Text] [Related]
10. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
13. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.
Segura Fábrega A; Pérez Catalán I; Gómez Alfaro I; García Muñoz S; Roig Martí C; Rodríguez Lozano N; Folgado Escudero S; Varea Villanueva M; Gascón Buj A; Torres García M; Reig Valero R; Ferrando Piqueres R; Usó Blasco J
Rev Esp Quimioter; 2023 Dec; 36(6):655-657. PubMed ID: 37786958
[TBL] [Abstract][Full Text] [Related]
14. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Sutanto ST; Sinto R; Pasaribu A; Shakinah S
Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients.
Pérez Catalán I; García Muñoz S; Roig Martí C; Gómez Alfaro I; Serrano Picazo L; Torres García M; Reig Valero R; Ferrando Piqueres R; Mateu Campos L; Ramos Rincón JM; Usó Blasco J
Rev Esp Quimioter; 2022 Dec; 35(6):589-591. PubMed ID: 36250675
[No Abstract] [Full Text] [Related]
16. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
[TBL] [Abstract][Full Text] [Related]
17. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.
Hirotsu Y; Kobayashi H; Kakizaki Y; Saito A; Tsutsui T; Kawaguchi M; Shimamura S; Hata K; Hanawa S; Toyama J; Miyashita Y; Omata M
Med; 2023 Nov; 4(11):813-824.e4. PubMed ID: 37683636
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Ford ES; Simmons W; Karmarkar EN; Yoke LH; Braimah AB; Orozco JJ; Ghiuzeli CM; Barnhill S; Sack CL; Benditt JO; Roychoudhury P; Greninger AL; Shapiro AE; Hammond JL; Rusnak JM; Dolsten M; Boeckh M; Liu C; Cheng GS; Corey L
Clin Infect Dis; 2023 Mar; 76(5):926-929. PubMed ID: 36326680
[TBL] [Abstract][Full Text] [Related]
20. Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients.
Chan M; Linn MMN; O'Hagan T; Guerra-Assunção JA; Lackenby A; Workman S; Dacre A; Burns SO; Breuer J; Hart J; Tadros S; Lowe DM
J Clin Immunol; 2023 Aug; 43(6):1083-1092. PubMed ID: 37148422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
